KYMR Q3 2021 Earnings — Kymera Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KYMRKymera Therapeutics, Inc.

$7B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$20M+39.9% YoY

Gross Profit

$20M100.0% margin

Operating Income

-$29M-140.8% margin

Net Income

-$29M-140.5% margin

EPS (Diluted)

$-0.56

QoQ Revenue Growth

+9.8%

Cash Flow

Operating Cash Flow

-$37M

Free Cash Flow

-$38M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$642M

Total Liabilities

$159M

Stockholders' Equity

$483M

Cash & Equivalents

$157M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$20M	$15M	+39.9%
Gross Profit	$20M	$15M	+39.9%
Operating Income	-$29M	-$8M	-254.3%
Net Income	-$29M	-$8M	-257.9%